BRD0705
BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM) . BRD0705 can be used for acute myeloid leukemia (AML) research[1].
Product Specifications
CAS Number
2056261-41-5
Product Name Alternative
UK-116865
UNSPSC
12352005
Target
GSK-3
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brd0705.html
Purity
99.86
Solubility
DMSO : 300 mg/mL (ultrasonic)
Smiles
O=C1C2=C(N=C3C([C@]2(CC)C4=CC=CC=C4)=CNN3)CC(C)(C)C1
Molecular Formula
C20H23N3O
Molecular Weight
321.42
References & Citations
[1]Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10 (431) . pii: eaam8460.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
GSK-3α; GSK-3β
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6425004-01 0.1 mL
LTA (Lymphotoxin-alpha, LT, Tumor Necrosis Factor beta, TNFB, TNFSF1) (HRP)
Sign In for Pricing
View Details MBS6425004-02 5x 0.1 mL
LTA (Lymphotoxin-alpha, LT, Tumor Necrosis Factor beta, TNFB, TNFSF1) (HRP)
Sign In for Pricing
View Details 
